1. Home
  2. PBHC vs SKYE Comparison

PBHC vs SKYE Comparison

Compare PBHC & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PBHC
  • SKYE
  • Stock Information
  • Founded
  • PBHC 1859
  • SKYE 2012
  • Country
  • PBHC United States
  • SKYE United States
  • Employees
  • PBHC N/A
  • SKYE N/A
  • Industry
  • PBHC Major Banks
  • SKYE Biotechnology: Pharmaceutical Preparations
  • Sector
  • PBHC Finance
  • SKYE Health Care
  • Exchange
  • PBHC Nasdaq
  • SKYE Nasdaq
  • Market Cap
  • PBHC 92.0M
  • SKYE 108.5M
  • IPO Year
  • PBHC N/A
  • SKYE N/A
  • Fundamental
  • Price
  • PBHC $14.98
  • SKYE $4.25
  • Analyst Decision
  • PBHC
  • SKYE Buy
  • Analyst Count
  • PBHC 0
  • SKYE 7
  • Target Price
  • PBHC N/A
  • SKYE $15.50
  • AVG Volume (30 Days)
  • PBHC 5.1K
  • SKYE 294.2K
  • Earning Date
  • PBHC 10-29-2025
  • SKYE 11-06-2025
  • Dividend Yield
  • PBHC 2.67%
  • SKYE N/A
  • EPS Growth
  • PBHC N/A
  • SKYE N/A
  • EPS
  • PBHC 0.28
  • SKYE N/A
  • Revenue
  • PBHC $39,015,000.00
  • SKYE N/A
  • Revenue This Year
  • PBHC N/A
  • SKYE N/A
  • Revenue Next Year
  • PBHC N/A
  • SKYE N/A
  • P/E Ratio
  • PBHC $53.37
  • SKYE N/A
  • Revenue Growth
  • PBHC N/A
  • SKYE N/A
  • 52 Week Low
  • PBHC $13.71
  • SKYE $1.14
  • 52 Week High
  • PBHC $19.86
  • SKYE $6.51
  • Technical
  • Relative Strength Index (RSI)
  • PBHC 54.73
  • SKYE 66.34
  • Support Level
  • PBHC $14.86
  • SKYE $3.96
  • Resistance Level
  • PBHC $15.50
  • SKYE $4.35
  • Average True Range (ATR)
  • PBHC 0.21
  • SKYE 0.28
  • MACD
  • PBHC 0.02
  • SKYE 0.09
  • Stochastic Oscillator
  • PBHC 35.00
  • SKYE 91.15

About PBHC Pathfinder Bancorp Inc. (MD)

Pathfinder Bancorp Inc is a holding company for Pathfinder Bank. The Pathfinder Bank is a commercial bank engaged in attracting deposits from the general public and investing such deposits, together with other sources of funds, in loans secured by residential real estate, commercial real estate, small business loans, and consumer loans. The bank invests a portion of its assets in debt securities issued by the United States Government and its agencies and sponsored enterprises, state and municipal obligations, corporate debt securities, mutual funds, and equity securities. The principal source of income is interest on loans and investment securities.

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: